Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
暂无分享,去创建一个
K. Chayama | K. Arihiro | S. Yamagishi | M. Takeuchi | H. Hyogo | Y. Nabeshima | Tomokazu Ishitobi | Yuki Kimura
[1] S. Yamagishi,et al. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. , 2010, Pharmacological research.
[2] K. Chayama,et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. , 2008, Metabolism: clinical and experimental.
[3] S. Yamagishi,et al. Advanced glycation end products (AGEs) and their involvement in liver disease. , 2008, Current pharmaceutical design.
[4] T. Imaizumi,et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein‐1 (MCP‐1) levels in patients with type 2 diabetes , 2008, Diabetes/metabolism research and reviews.
[5] K. Chayama,et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells , 2008, Journal of Gastroenterology.
[6] T. Imaizumi,et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects , 2007, Clinical and Experimental Medicine.
[7] K. Chayama,et al. Elevated levels of serum advanced glycation end products in patients with non‐alcoholic steatohepatitis , 2007, Journal of gastroenterology and hepatology.
[8] T. Imaizumi,et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes , 2006, Clinical and Experimental Medicine.
[9] K. Tsuneyama,et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis , 2006, Journal of Gastroenterology.
[10] J. Gisbert,et al. A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients , 2006, Alimentary pharmacology & therapeutics.
[11] A. Burroughs,et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.
[12] N. Yoshiike,et al. Epidemiological aspects of obesity and NASH/NAFLD in Japan. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.
[13] T. Imaizumi,et al. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.
[14] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[15] G. Lazaraki,et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
[16] K. Lindor,et al. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
[17] P Christoffersen,et al. Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.
[18] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[19] 稲垣 洋介. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation , 2004 .
[20] S. Gurel,et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] E. Van Obberghen,et al. Human Glycated Albumin Affects Glucose Metabolism in L6 Skeletal Muscle Cells by Impairing Insulin-induced Insulin Receptor Substrate (IRS) Signaling through a Protein Kinase Cα-mediated Mechanism* , 2003, Journal of Biological Chemistry.
[22] J. Hui,et al. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them , 2003, Journal of Gastroenterology and Hepatology.
[23] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.
[24] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[25] A. Jaffe,et al. Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.
[26] T. Imaizumi,et al. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. , 2003, International journal of clinical pharmacology research.
[27] Z. Makita,et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. , 2002, Biochemical and biophysical research communications.
[28] K. Miyata,et al. Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. , 2002, Biochimica et biophysica acta.
[29] R. Karim,et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.
[30] Hiroshi Yamamoto,et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. , 2002, Biochemical and biophysical research communications.
[31] G. Marchesini,et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.
[32] S. Takasawa,et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.
[33] P. Aspichueta,et al. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. , 2000, Atherosclerosis.
[34] K. Kawasaki,et al. Roles of the AGE‐RAGE System in Vascular Injury in Diabetes a , 2000, Annals of the New York Academy of Sciences.
[35] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[36] R. Bucala,et al. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo , 2000, Molecular medicine.
[37] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[38] C. Day,et al. Non-alcoholic steatohepatitis: another disease of affluence , 1999, The Lancet.
[39] C. Bisgaier,et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. , 1998, Atherosclerosis.
[40] M. Bennett,et al. The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.
[41] D. Whalan. The ethics and morality of clinical trials in man. , 1975, The Medical journal of Australia.